← All Compounds
Mechanism Activates both GIP and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through complementary incretin pathways. Half-Life Approximately 5 days (120 hours) Route subcutaneous Frequency Once weekly
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
Tirzepatide
FDA ApprovedDual Agonist · Eli Lilly
Dual GIP/GLP-1 receptor agonist for type 2 diabetes and chronic weight management. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
About
Clinical Dosing
2.5-15 mgonce weekly
Titration Protocols
Mounjaro Label Titration
Source: Mounjaro (tirzepatide) prescribing information, Eli Lilly, 2022
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 2.5 mg | 4 weeks | 1.00 mL (100 units) | Starting dose |
| 5 mg | 4 weeks | 2.00 mL (200 units) | First escalation |
| 7.5 mg | 4 weeks | 3.00 mL (300 units) | Second escalation |
| 10 mg | 4 weeks | 4.00 mL (400 units) | Third escalation |
| 12.5 mg | 4 weeks | 5.00 mL (500 units) | Fourth escalation |
| 15 mg | Maintenance | 6.00 mL (600 units) | Maximum dose |
Available Vial Sizes
5 mg
5 mg vial
10 mg
10 mg vial
15 mg
15 mg vial
30 mg
30 mg vial